
CLAIMS

What is claimed is:

1. Use of a compound represented by the following structural formula:




;

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the intravenous treatment of a human patient with acute kidney injury.

2. The use of claim 1, wherein an effective amount of the meglumine salt of the compound is to be intravenously administered to the patient.


3. Use of a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a human patient with acute kidney injury.

4. Use of a compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt theof in the manufacture of a medicament for the treatment of a human patient with acute kidney injury.

5. The use of claim 3 or 4, wherein the compound is to be administered intravenously.

6. The use of claim 3 or 4, wherein the compound is to be administered orally.

7. The use of any one of claims 1–6, wherein the patient is to be treated for acute kidney injury from acute interstitial nephritis.

8. The use of any one of claims 1–6, wherein the patient is to be treated for acute kidney injury from glomerular renal disease.

9. The use of any one of claims 1–6, wherein the patient is to be treated for acute kidney injury from acute vasculitic renal disease.

10. The use of any one of claims 1–6, wherein the patient is to be treated for acute kidney injury from ischemia.

11. The use of any one of claims 1–6, wherein the patient is to be treated for acute kidney injury from toxic injury.

12. The use of any one of claims 1–6, wherein the patient is to be treated for acute kidney injury from prerenal axotemia.

13. The use of any one of claims 1–6, wherein the patient is to be treated for acute kidney injury from acute postrenal destructive nephropathy.

14. The use of any one of claims 1–6, wherein the patient is to be treated for acute kidney injury from diabetes, underlying renal insufficiency, nephritic syndrome, atherosclerotic disease, sepsis, hypotension, hypoxia, myoglobinuria-hematuria, or liver disease.


15. The use of any one of claims 1–6, wherein the patient to be treated for acute kidney injury is elderly, pregnant, a surgical patient, or has been exposed to a nephrotoxic agent.

16. The use of claim 15, wherein the patient is a surgical patient.

17. The use of claim 15, wherein the patient has been exposed to a nephrotoxic agent and the nephrotixuc agent is a drug or chemical capable of causing acute kidney injury.

18. The use of claim 17, wherein the drug or chemical is one or more of the compounds selected from the group consisting of cisplatin; gentamicin; cephaloridine; cyclosporine; amphotericin; carbon tetrachloride; trichloroethylene; and dichloroacetylene.


19. A compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, for use in the intravenous treatment of a human patient with acute kidney injury.


20. A compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, for use in the treatment of a human patient with acute kidney injury.

21. A compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, for use in the treatment of a human patient with acute kidney injury.